TY - JOUR
T1 - Colon cancer, version 3.2014
AU - Benson, Al B.
AU - Venook, Alan P.
AU - Bekaii-Saab, Tanios
AU - Chan, Emily
AU - Chen, Yi Jen
AU - Cooper, Harry S.
AU - Engstrom, Paul F.
AU - Enzinger, Peter C.
AU - Fenton, Moon J.
AU - Fuchs, Charles S.
AU - Grem, Jean L.
AU - Hunt, Steven
AU - Kamel, Ahmed
AU - Leong, Lucille A.
AU - Lin, Edward
AU - Messersmith, Wells
AU - Mulcahy, Mary F.
AU - Murphy, James D.
AU - Nurkin, Steven
AU - Rohren, Eric
AU - Ryan, David P.
AU - Saltz, Leonard
AU - Sharma, Sunil
AU - Shibata, David
AU - Skibber, John M.
AU - Sofocleous, Constantinos T.
AU - Stoffel, Elena M.
AU - Stotsky-Himelfarb, Eden
AU - Willett, Christopher G.
AU - Gregory, Kristina M.
AU - Freedman-Cass, Deborah A.
N1 - Copyright © 2014 by the National Comprehensive Cancer Network.
PY - 2014/7/1
Y1 - 2014/7/1
N2 - The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.
AB - The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.
KW - Angiogenesis Inhibitors/adverse effects
KW - Antibodies, Monoclonal, Humanized/adverse effects
KW - Antineoplastic Agents/adverse effects
KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects
KW - Bevacizumab
KW - Camptothecin/adverse effects
KW - Capecitabine
KW - Cetuximab
KW - Colonic Neoplasms/drug therapy
KW - Deoxycytidine/adverse effects
KW - Disease Progression
KW - Fluorouracil/adverse effects
KW - GTP Phosphohydrolases/genetics
KW - Humans
KW - Leucovorin/adverse effects
KW - Liver Neoplasms/drug therapy
KW - Membrane Proteins/genetics
KW - Organoplatinum Compounds/adverse effects
KW - Oxaloacetates
KW - Proto-Oncogene Proteins B-raf/genetics
KW - Proto-Oncogene Proteins p21(ras)
KW - Proto-Oncogene Proteins/genetics
KW - Treatment Outcome
KW - ras Proteins/genetics
UR - http://www.scopus.com/inward/record.url?scp=84903980978&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000338901800010&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.6004/jnccn.2014.0099
DO - 10.6004/jnccn.2014.0099
M3 - Article
C2 - 24994923
SN - 1540-1405
VL - 12
SP - 1028
EP - 1059
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 7
ER -
